Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-03
2006-10-03
Lambkin, Deborah C. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S369000, C514S370000, C548S180000, C548S190000
Reexamination Certificate
active
07115640
ABSTRACT:
Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of farnesoid X receptor (FXR), liver X receptor (LXR) and/or orphan nuclear receptors. In certain embodiments, the compounds are thiazolidinone derivatives.
REFERENCES:
patent: 2388963 (1945-11-01), Fre et al.
patent: 2454629 (1948-11-01), Brooker
patent: 3627534 (1971-12-01), Shiba et al.
patent: 3635964 (1972-01-01), Skorcz et al.
patent: 3710795 (1973-01-01), Higuchi et al.
patent: RE28819 (1976-05-01), Thompson
patent: 4044126 (1977-08-01), Cook et al.
patent: 4093730 (1978-06-01), Butti et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4258185 (1981-03-01), Nakao et al.
patent: 4328245 (1982-05-01), Yu et al
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4358603 (1982-11-01), Yu
patent: 4364923 (1982-12-01), Cook et al.
patent: 4409239 (1983-10-01), Yu
patent: 4410545 (1983-10-01), Yu et al.
patent: 4414209 (1983-11-01), Cook et al.
patent: 4444784 (1984-04-01), Hoffman et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4916128 (1990-04-01), Jonas et al.
patent: 4933336 (1990-06-01), Martin et al.
patent: 5033252 (1991-07-01), Carter
patent: 5052558 (1991-10-01), Carter
patent: 5070012 (1991-12-01), Nolan et al.
patent: 5071773 (1991-12-01), Evans et al.
patent: 5171851 (1992-12-01), Kim et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5221623 (1993-06-01), Legocki et al.
patent: 5273995 (1993-12-01), Roth
patent: 5283173 (1994-02-01), Fields et al.
patent: 5298429 (1994-03-01), Evans et al.
patent: 5323907 (1994-06-01), Kalvelage
patent: 5354772 (1994-10-01), Kathawala
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5468614 (1995-11-01), Fields et al.
patent: 5476945 (1995-12-01), Ikegawa et al.
patent: 5618831 (1997-04-01), Shishido et al.
patent: 5650289 (1997-07-01), Wood
patent: 5667973 (1997-09-01), McElroy et al.
patent: 5670530 (1997-09-01), Chen et al.
patent: 5674713 (1997-10-01), McElroy et al.
patent: 5683888 (1997-11-01), Campbell
patent: 5707794 (1998-01-01), Fabricius
patent: 5741657 (1998-04-01), Tien et al.
patent: 5757661 (1998-05-01), Surville
patent: 5843746 (1998-12-01), Tatsumi et al.
patent: 5955604 (1999-09-01), Tsien et al.
patent: 6071955 (2000-06-01), Elias et al.
patent: 6184215 (2001-02-01), Elias et al.
patent: 6187814 (2001-02-01), Elias et al.
patent: 6291676 (2001-09-01), Burke et al.
patent: 6316510 (2001-11-01), Sperber
patent: 6416957 (2002-07-01), Evans et al.
patent: 6452032 (2002-09-01), Beard et al.
patent: 6458789 (2002-10-01), Forood et al.
patent: 6521666 (2003-02-01), Sircar et al.
patent: 6541486 (2003-04-01), Bitler et al.
patent: 6548505 (2003-04-01), Martin et al.
patent: 6559168 (2003-05-01), Marfat et al.
patent: 6569874 (2003-05-01), Pruitt et al.
patent: 6586453 (2003-07-01), Dhanoa et al.
patent: 6696473 (2004-02-01), Martin et al.
patent: 2002/0120137 (2002-08-01), Houze et al.
patent: 2002/0132223 (2002-09-01), Forman et al
patent: 2003/0181420 (2003-09-01), Bayne et al.
patent: 2003/0228607 (2003-12-01), Wagner et al.
patent: 1908570 (1969-02-01), None
patent: 0454330 (1991-04-01), None
patent: 0510235 (1991-04-01), None
patent: 0985683 (1999-09-01), None
patent: 1449800 (1964-07-01), None
patent: 2117337 (1971-03-01), None
patent: 53129633 (1978-11-01), None
patent: 527356 (1993-02-01), None
patent: 620053 (1994-08-01), None
patent: 6234639 (1994-08-01), None
patent: 6293642 (1994-10-01), None
patent: 200113617 (2001-01-01), None
patent: 8402131 (1984-06-01), None
patent: 8603749 (1986-07-01), None
patent: 9104974 (1991-04-01), None
patent: 9518380 (1995-07-01), None
patent: 9707101 (1997-02-01), None
patent: 9832444 (1998-07-01), None
patent: 9927365 (1999-06-01), None
patent: 0017334 (2000-03-01), None
patent: 0025134 (2000-05-01), None
patent: 0037077 (2000-06-01), None
patent: 0040965 (2000-07-01), None
patent: 0042031 (2000-07-01), None
patent: 0049992 (2000-08-01), None
patent: 0057915 (2000-10-01), None
patent: 0076523 (2000-12-01), None
patent: 0078972 (2000-12-01), None
patent: 0117994 (2001-03-01), None
patent: 0120137 (2001-03-01), None
patent: 0123887 (2001-04-01), None
patent: 0160818 (2001-08-01), None
patent: 0182917 (2001-11-01), None
patent: 0211708 (2002-02-01), None
patent: 02064125 (2002-08-01), None
patent: 02072598 (2002-09-01), None
patent: 03059884 (2003-07-01), None
patent: 03060078 (2003-07-01), None
patent: 03076418 (2003-09-01), None
patent: 03099821 (2003-12-01), None
patent: 03106435 (2003-12-01), None
“Hypolipidemics, HMG-CoA Reductase Inhibitors,”Physicians' Desk Reference(PDR), 50th Ed, (Medical Economics Co), pp. 216 (1996).
Alberti et al., “Structural characterisation of the mouse nuclear oxysterol receptor genes LXRα and LXRβ”,Gene, 243:93-103 (2000).
Ansel, H.C., (Eds.), inIntroduction to Pharmaceutical Dosage Forms Fourth Edition, Philadelphia: Lea & Febiger, pp. 125 (1985).
Augustin et al., “Umsetzung des Thiazolo [3,2-a] benzimidazol-3-ons mit Elektrophilen [Reactions of thiazolo [3,2-a]benzimidazol-3-one with electrophiles]”,Zeitschrift fur Chemie, 29(6):206-207 (1989).
Barrett-Connor, “Epidemiology, Obesity, and Non-Insulin-Dependent Diabetes Mellitus”,Epidemiologic Reviews, 11:172-181 (1989).
Bellec et al., “Dicationic State of Dithiadiazafulvalene within a TCNQ Charge-Transfer Complex: Generation and Characterization”,Chem. Mater., 11:3147-3153 (1999).
Berger et al., “Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells”,Gene, 66:1-10 (1988).
Bronstein et al., “1,2-Dioxetanes: Novel Chemiluminescent Enzyme Substrates. Applications to Immunoassays”,Journal of Bioluminescence and Chemiluminescence, 4:99-111 (1989).
Carceller et al., “Design, Synthesis, and Structure-Activity Relationship Studies of Novel 1 -[(1-Acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c] pyridine Derivatives as Potent, Orally Active Platelet-Activating Factor Antagonists”,J. Med. Chem., 39:487-493 (1996).
Chiang et al., “Farnesoid X Receptor Responds to Bile Acids and Represses Cholesterol 7α-Hydroxylase Gene (CYP7A1) Transcription”,Journal of Biological Chemistry, 275(15):10918-10924 (2000).
Chiasson et al., “The Efficacy of Acarbose in the Treatment of Patients with Non-Insulin-dependent Diabetes Mellitus”,Ann. Intern. Med, 121:928-935 (1994).
Chiba et al., “Distinct Retinoid X Receptor-Retinoic Acid Receptor Heterodimers Are Differentially Involved in the Control of Expression of Retinoid Target Genes in F9 Embryonal Carcinoma Cells”,Molecular and Cellular Biology, 17(6):3013-3020 (1997).
Coniff, R. and A. Krol, “Acarbose: A Review of US Clinical Experience”,Clinical Therapeutics, 19(1):16-26 (1997).
Coniff et al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus”,American Journal of Medicine, 98:443-451 (1995).
Dains et al., “The Reactions of the Formamidines. VIII. Some Thiazolidone Derivatives”,J. Am. Chem. Soc., 43:613-618 (1921).
Davis, J.A. and F.B. Dains, “Some Alkyl Derivatives of Certain Aryl Substituted Thiazolidones”,J. Am. Chem. Soc., 57:2627-2630 (1935).
Derwent WPI Acc. No. 13863260 citing Japanese Patent 2001-13617, “Silver halide emulsion, silver halide photosensitive material and thermally developable photosensitve material”.
Derwent WPI Acc. No. 9387756 citing Japanese Patent 5-27356, “Silver halide photographic material—contains silver halide particles spectrally sensitised with novel merocyanine dye”.
Derwent# 000911469, WPI Acc. No. 1972-71638T/197245 (citing French Patent No. 2117337), “Merocyanine dye sensitisers—contg basic and acidic gps for silver halide emulsions”.
Derwent# 0100
Flatt Brenton T
Kahl Jeffrey D
Martin Richard
Wang Tie-Lin
Lambkin Deborah C.
McDonnell Boehnen & Hulbert & Berghoff LLP
X-Ceptor Therapeutics, Inc.
LandOfFree
Heterocyclic modulators of nuclear receptors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic modulators of nuclear receptors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic modulators of nuclear receptors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3644084